Advancing
Cancer Detection

Our mission at Elypta is to prevent cancer mortality through earlier detection and closer monitoring  

iStock-650191372.jpg
Empty.png

Liquid biopsies

meet metabolism

We measure metabolic biomarkers in blood and urine and use machine learning to detect signatures of cancer

Connected man original.jpg
 

Why a liquid biopsy based on metabolism?

Medical imaging and tissue biopsies - the current gold standard in most indications - are ill-suited for close tracking of disease as they are associated with risks, high costs and inconvenience for patients.

Molecular approaches could provide a solution. However, single molecule biomarkers are not sensitive or specific enough for the vast majority of cancers.

 
a6b0ac.png
 

Elypta’s approach is to measure a system of metabolic biomarkers - a profile of metabolites found to reflect an important process in cancer - in both blood and urine.

Our learning algorithms then pin down the patterns specific to various forms of cancer using clinical data.

 
Connected dots original.jpg

Core
Activities

Elypta is developing a liquid biopsy platform based on a scalable laboratory assay and artificial intelligence algorithms trained by our clinical database.

Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in our lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. We also explore several other indications to understand the full potential for Elypta’s platform. 

co-funded-h2020-horiz_en.png
0087c1.png
 

Help us advance
cancer detection

 
 

Collaborate

We welcome partnerships with academia to explore clinical applications across indications as well as industry for development of companion diagnostics

 

Join us

Elypta is looking to expand the team on all levels, feel free to contact us

 

Invest

We welcome interest from investors and are happy to provide more information on Elypta’s plans for development and commercialisation on request